BOM:543245

Kotak Securities Upgrades Gland Pharma to Add From Reduce; Price Target is INR2,075

Nomura Adjusts Gland Pharma's Price Target to INR2,390 from INR2,000, Keeps at Buy

Jefferies Adjusts Gland Pharma's Price Target to INR2,080 from INR1,720, Keeps at Hold

Gland Pharma's Consolidated Attributable Profit Almost Doubles in Fiscal Q4

Gland Pharma's (NSE:GLAND, BOM:543245) attributable consolidated profit almost doubled to 3.67 billion Indian rupees in the fiscal fourth quarter from 1.87 billion rupees a year ago.Earnings per share jumped to 22.23 rupees from 11.32 rupees over the period, according to a Friday filing to the Indian stock exchanges by the pharmaceutical company.Revenue from operations during the quarter also increased to 17.43 billion rupees from 14.25 billion rupees a year earlier.The company's board recommended a final dividend of 20 rupees per share for the financial year ended March 31.